Brainstorm cell therapeutics announces in-person meeting with the fda to discuss confirmatory phase 3 trial for nurown® in als

Meeting will take place on december 6; company plans to seek special protocol assessment (spa) new york , nov. 20, 2023 /prnewswire/ --brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the us food & drug administration (us fda) has granted the company a meeting to discuss the regulatory path forward for nurown® in amyotrophic lateral sclerosis (als). the meeting is scheduled to take place on december 6, 2023.
BCLI Ratings Summary
BCLI Quant Ranking